Abstracts tagged "Biologicals"

Abstract Number: 0827 • ACR Convergence 2024
Oral Corticosteroid-Sparing Effects of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Results up to 7.4 Years from the Long-Term Access Programme
Paneez Khoury¹, Jared Silver², Gerhard Wolff³, Robert Price⁴, Rejina Verghis⁵, Emmeline Igboekwe² and Michael E Wechsler⁶, ¹National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ²US Medical Affairs-Respiratory, GSK, Durham, ³Clinical Development-Respiratory, GSK, Collegeville, ⁴Biostatistics, GSK, Stevenage, United Kingdom, ⁵Biostatistics, Development Respiratory, GSK, Brentford, United Kingdom, ⁶Department of Medicine, National Jewish Health, Denver, CO
Background/Purpose: EGPA is a severe, rare, relapsing/remitting inflammatory disease, in which chronic or high oral corticosteroid (OCS) doses lead to adverse effects, adding to disease…
Abstract Number: 1120 • ACR Convergence 2024
Long-Term Echocardiographic Findings in Idiopathic Recurrent Pericarditis Patients Treated with Anakinra
Zeynep Toker Dincer¹, Damla Raimoglu², Erkin Yilmaz³, Ayten Dag¹, Sejla Karup⁴, Melike Melikoglu¹ and Serdal Ugurlu⁵, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Cardiology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, Turkey, ⁴Cerrahpasa Faculty of Medicine, Istanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Istanbul, Turkey
Background/Purpose: Idiopathic recurrent pericarditis (IRP) is characterized by recurrent pericarditis attacks, and autoinflammatory pattern has been highlighted due to similarities in both clinical features and…
Abstract Number: 1455 • ACR Convergence 2024
Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients with Psoriatic Arthritis
Fadi Kharouf¹, Shangyi Gao², Ali Alhadri², Daniel Pereira³, Richard Cook⁴, Vinod Chandran⁵ and Dafna Gladman⁶, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Waterloo, Waterloo, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Secondary failure to biologic therapy is challenging and contributes to the complexity of managing psoriatic arthritis (PsA). In this study, we aimed to define…
Abstract Number: 1548 • ACR Convergence 2024
Anifrolumab in Systemic Lupus Erythematosus. Spanish National Registry in a Real-world Setting
Carmen Secada Gómez¹, Vanesa Calvo-Rio², Miriam Retuerto Guerrero³, Judit Font⁴, Ivette Casafont-Sole⁵, Adrián Mayo-Juanatey⁶, Juan José Alegre Sancho⁶, Dalifer Freites Nuñez⁷, Cristina Hormigos⁸, Noemí Garrido-Puñal⁹, GUILLERMO GONZALEZ ARRIBAS¹⁰, Andrea García-Valle¹¹, Juan Roberto Miguelez Sanchez¹², Marta Ibáñez Martínez¹³, Fernando Lozano Morillo¹⁴, Ángel García Manzanares¹⁵, Sebastián Sandoval-Moreno¹⁶, Josefina Cortés-Hernández¹⁷, Desiree Palma¹⁸, Leticia Lojo Oliveira¹⁹, EVELIN CERVANTES PEREZ²⁰, PAZ COLLADO²¹, Cristina Arciniega Larios²², Luis Sala Icardo²³, Eztizen Labrador-Sánchez²⁴, Cilia Peralta Ginés²⁵, Nahia Plaza-Aulestia²⁶, Miguel Medina Malone²⁷, José Rosas-Gómez de Salazar²⁸, Montserrat Corteguera²⁹, Laura Cebrián¹⁹, Fred Anton Pages³⁰, JOSE RAMON LAMUA RIAZUELO³¹, maria Dolores Fábregas canales³², María José Alados Hernández³³, Marta Garijo Bufort³⁴, Anna Pamies Corts³⁵, Luis Sarabia De Ardanaz³⁶, Rodrigo Aguirre-del-Pino³⁷, José Ángel Cabezas Lefler³⁸, Álvaro Seijas-Lopez³⁷, Carmen Carrasco-Cubero³⁹, Ana López-Cerón Cofiño⁴⁰, Vera Ortiz-Santamaria⁴¹, Santos Castañeda⁴², María Laiño Piñeiro⁴³, Carmen Ordás Calvo⁴⁴, Celia Arconada Lopez⁴⁵, Carmen Bejerano⁴⁶ and Ricardo Blanco-Alonso⁴⁷, ANA URRUTICOECHEA⁴⁸, Blanca Garcia-Magallon⁴⁹, Ana Valeria Acosta Alfaro⁵⁰, Samuel Leal Rodriguez⁵¹, Marina Salido Olivares⁵² and Patricia Lavilla⁵³ ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Valdecilla Hospital, Santander, Cantabria, Spain, ³Complejo Asistencial Universitario de León, Leon, Spain, ⁴Hospital Germans Trias i Pujol, Barcelona, Spain, ⁵Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁶Hospital Universitario Doctor Peset, Valencia, Spain, ⁷Hospital Clínico San Carlos. Madrid. Spain., Madrid, Spain, ⁸Hospital Clínico San Carlos, Madrid, Madrid, Spain, ⁹Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹⁰Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹¹Hospital General Río Carrión, Palencia, Spain, ¹²Hospital Universitario de Móstoles, Madrid, Spain, ¹³Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ¹⁴Hospital Central de La Defensa Gómez Ulla, Madrid, Spain, ¹⁵Hospital Universitario de Torrevieja, Alicante, Spain, ¹⁶Hospital Universitario Vall d´Hebrón, Barcelona, Spain, ¹⁷Hospital Universitario Vall d´Hebrón Hospitals, Barcelona, ES, Barcelona, Spain, ¹⁸Hospital Rafael Méndez, Lorca, Murcia, Spain, ¹⁹Hospital Universitario Infanta Leonor, Madrid, Spain, ²⁰Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain, ²¹Hospital Universitario Severo Ochoa, MADRID, Spain, ²²Hospital de Mérida, Badajoz, Spain, ²³Hospital Universitario de Torrejón, Madrid, Spain, ²⁴Hospital General de La Rioja, Logroño, Spain, ²⁵Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ²⁶Hospital Galdakao, Vizcaya, Spain, ²⁷Hospital Calahorra, La Rioja, Spain, ²⁸Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ²⁹ComplejoAsistencial de Ávila, Ávila, Spain, ³⁰Complejo Asistencial De Segovia, Segovia, Spain, ³¹Hospital Universitario del Henares, Madrid, Spain, ³²Hospital de Barbastro, Huesca, Spain, ³³Hospital Universitario Puerta del Mar, Cádiz, Spain, ³⁴Hospital de Sagunto, Valencia, Spain, ³⁵Hospital Verge de la Cinta, Tortosa, TARRAGONA, Spain, ³⁶Complejo Hospitalario de Jaén, Jaén, Spain, ³⁷Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁸Complejo Asistencial de Zamora, Zamora, Spain, ³⁹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ⁴⁰Hospital Santa Bárbara, Soria, Spain, ⁴¹Hospital General de Granollers, Barcelona, Spain, ⁴²Hospital Universitario de la Princesa, Madrid, Spain, ⁴³Hospital Universitario de Navarra, Pamplona, Spain, ⁴⁴Hospital Universitario de Cabueñes, Gijón, Spain, ⁴⁵Hospital Universitario Infanta Elena, Valdemoro, Madrid, Spain, ⁴⁶Hospital Universitario Marques de Valdecilla, Immunopathology group, IDIVAL, Santander, Cantabria, Spain, ⁴⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁴⁸Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain, ⁴⁹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, ⁵⁰Hospital Universitario Infanta Sofía, Madrid, Spain, ⁵¹HUP La Fe, Valencia, Spain, ⁵²Hospital Infanta Cristina, Parla, Spain, ⁵³Hospital General de Villalba, Collado Villalba, Spain
Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody that binds to the type I interferon receptor subunit 1 (IFNAR1), thus blocking the biological activity of…
Abstract Number: 1997 • ACR Convergence 2024
Features of interleukin-1 and interleukin-6 Inhibitor (IL-1i/IL-6i) Related Severe Delayed Adverse Reactions in Subjects with or Without Reaction-risk Associated HLA-DRB1*15
Vivian E Saper¹, Kazutoyo Osoegawa¹, Ruud Verstegen², Marcelo A Fernandez Vina¹ and Lu Tian¹, and Drug Hypersensitivity Consortium, ¹Stanford University, Stanford, CA, ²The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: A very serious drug-related adverse event is reported with inhibitors of IL-1 and IL-6 (IL-1i/IL6i). This reaction scores as drug reaction with eosinophilia and…
Abstract Number: 2270 • ACR Convergence 2024
Low Yield of Routine Serological Screening for Hepatitis B in Patients with Rheumatoid Arthritis Starting Rituximab Therapy in a Non-Endemic Country
Pauline Bovens¹, Maike Wientjes¹, Nathan den Broeder², David Ten Cate³, Aatke Van der maas⁴ and Alfons den Broeder¹, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ³Sint Maartenskliniek, Rotterdam, Netherlands, ⁴St Maartenskliniek, Ubbergen, Netherlands
Background/Purpose: Rituximab (RTX) is an effective and safe treatment for patients with RA, but is associated with an increased risk for reactivation of hepatitis B virus…
Abstract Number: 2479 • ACR Convergence 2024
Mepolizumab Treatment Decreased Oral Corticosteroid Use and Improved Clinical Response, Control Status, and Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis: Results up to 24 Months from a Large Network of US Allergy Practices
Michael E Wechsler¹, Anna Kovalszki², Jared Silver³, Brian Stone⁴, Lior Seluk⁵, Lynn Huynh⁶, Wilson da Costa Junior⁶, Mingchen Ye⁶, Jeremiah Hwee⁷, Mei Sheng Duh⁶, William McCann⁴ and Amy G. Edgecomb⁸, ¹Department of Medicine, National Jewish Health, Denver, CO, ²Division of Allergy and Clinical Immunology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ³US Medical Affairs - Respiratory, GSK, Durham, ⁴Allergy Partners, Asheville, NC, ⁵Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, ⁶Analysis Group, Boston, MA, ⁷Value Evidence and Outcomes, GSK, Mississauga, Canada, ⁸US Value, Evidence, & Outcomes, Anti-Infectives and Respiratory, GSK, Philadelphia
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a severe rare systemic inflammatory disease characterized by elevated blood eosinophil counts ≥1000 cells/µL and vasculitis of small-…
Abstract Number: 0003 • ACR Convergence 2024
CLN-978, a CD19-directed T Cell Engager (TCE), Leads to Rapid and Deep B Cell Depletion and Has Broad Potential for Development in Autoimmune Diseases
Máire F. Quigley¹, Jennifer S. Michaelson¹, Jeffrey Jones¹, Farrukh T. Awan², Geoffrey P. Shouse³, Yue Zhang¹, Todd Shearer¹, Judy Inumerable¹, Irina M. Shapiro¹, Patrick A. Baeuerle¹ and Stephen Wax¹, ¹Cullinan Therapeutics, Inc., Cambridge, ²UT Southwestern Medical Center, Dallas, ³City of Hope Comprehensive Cancer Center, Duarte
Background/Purpose: CD19-directed CAR T cell therapy has been reported to induce profound B cell depletion and deep clinical responses, including drug-free remission, in patients with…
Abstract Number: 0393 • ACR Convergence 2024
Effectiveness of Secukinumab in TMJ Symptoms in Children with JPsA and ERA: A Secondary Data Analysis of JUNIPERA
Marianne Kerski¹, Smriti Mohan¹, Cynthia Vizcaya², Reema Sutariya³, Weibin Bao³ and Matthew Stoll⁴, ¹University of Michigan, Ann Arbor, MI, ²Novartis Pharmaceutical Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Early recognition and treatment of temporomandibular joint (TMJ) arthritis in children with juvenile idiopathic arthritis (JIA) is of high importance given its impact on…
Abstract Number: 0517 • ACR Convergence 2024
Characterizing Infusion-Related Reactions in Patients with Rheumatoid Arthritis Treated with Biologic DMARDs: Observations from the KOBIO Registry
Ji-Won Kim¹, Ju-Yang Jung², Chang-Hee Suh³ and Hyoun-Ah Kim¹, ¹Ajou university school of medicine, Suwon, South Korea, ²Ajou University of medical school, Suwon, South Korea, ³Ajou University Hospital, Suwon, South Korea
Background/Purpose: The use of biologic disease-modifying antirheumatic drugs (bDMARDs) has revolutionized the management of rheumatoid arthritis (RA), despite their efficacy being occasionally limited by infusion-related…
Abstract Number: 0591 • ACR Convergence 2024
Bimekizumab Maintained Efficacy Responses in Patients with Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies
Jessica A Walsh¹, Joseph F. Merola², Christopher T Ritchlin³, Yoshiya Tanaka⁴, Ennio Giulio Favalli⁵, Dennis McGonagle⁶, Diamant Thaçi⁷, Barbara Ink⁸, Rajan Bajracharya⁸, Jason Coarse⁹ and William Tillett¹⁰, ¹Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ²UT Southwestern Medical Center, Dallas, TX, ³Allergy, Immunology & Rheumatology Division, University of Rochester Medical School, Rochester, NY, ⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁵ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ⁶National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom, ⁷Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Schleswig-Holstein, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Morrisville, NC, ¹⁰Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom
Background/Purpose: PsA is a chronic disease, and patients (pts) can experience loss of response with sustained therapy; therefore, assessing long-term maintenance of response in pts…
Abstract Number: 0849 • ACR Convergence 2024
Effectiveness of Tocilizumab in Aortitis and Aneurysms Associated with Giant Cell Arteritis. Multicenter Open-label Study
Adrián Martín-Gutiérrez¹, Javier Loricera², Carmen Secada Gómez³, Iñigo Hernández-Rodríguez⁴, Susana Romero Yuste⁵, Eugenio De Miguel⁶, Eva Galindez-Agirregoikoa⁷, ivan Ferraz-Amaro⁸, Julio Sánchez-Martín⁹, Patricia Moya Albarado¹⁰, Cristina Campos Fernández¹¹, Fernando Lopez-Gutierrez¹², Santos Castañeda¹³ and Ricardo Blanco-Alonso¹⁴, and the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁵Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁸Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁰Hospital de San Pau, Barcelona, Spain, ¹¹Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, ¹²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ¹³Hospital Universitario de la Princesa, Madrid, Spain, ¹⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Giant Cell Arteritis (GCA) was initially described involving mainly the extracranial branches of the carotid arteries. However, GCA also may involve the aorta (GCA-aortitis)…
Abstract Number: 1132 • ACR Convergence 2024
Guselkumab and Golimumab Combination Induction Therapy in Ulcerative Colitis Results in Early Local Tissue Healing That Is Sustained Through Guselkumab Maintenance Therapy
Dylan Richards¹, Marion Vetter¹, Matthew Germinaro¹, Bram Verstockt², Raja Atreya³, Julián Panés⁴, Bruce E. Sands⁵, Brian G. Feagan⁶, Bradford McRae⁷, Daniel Cua¹, Patrick Branigan¹ and Tom C. Freeman¹, ¹Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, ²Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium, ³Department of Medicine I, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ⁴Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, Barcelona, Spain, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York, NY, ⁶Alimentiv Inc, London, ON, Canada, London, ON, Canada, ⁷Janssen Research & Development, Cambridge, MA, USA, Cambridge, MA
Background/Purpose: Combination induction therapy with guselkumab (GUS), an interleukin (IL)-23p19 subunit antagonist, and golimumab (GOL), a tumor necrosis factor (TNFα) antagonist, induced higher rates of…
Abstract Number: 1457 • ACR Convergence 2024
Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab versus Standard Care – 12- and 24-Week Results from a Multicenter, Open-Label, Randomized Controlled Trial
Gonul Hazal Koc¹, Marc R. Kok², Fazira R. Kasiem³, Jolanda Luime³, Ilja Tchetverikov⁴, Kim Wilhelm - de Jong³, Lindy A. Korswagen⁵, Jessica Bijsterbosch⁶, Yvonne P. M. Goekoop-Ruiterman⁷, Paul Baudoin⁸, Petra Kok⁹, Reinhard Bos¹⁰, radboud J.e.m. Dolhain¹¹ and Marijn Vis³, ¹Erasmus MC, Rotterdam, Zuid-Holland, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³Erasmus MC, Rotterdam, Netherlands, ⁴Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁵Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands, ⁶Amphia Hospital, North Brabant, Netherlands, ⁷Haga Hospital, Den Haag, Netherlands, ⁸Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁹Reinier de Graaf Gasthuis, Delft, Netherlands, ¹⁰Medical Center Leeuwarden, Leeuwarden, Netherlands, ¹¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: The Strategy Treatments aiming at Minimal Disease Activity in PsA (STAMP) is a one-year randomized controlled trial designed to investigate the efficacy of two…
Abstract Number: 1553 • ACR Convergence 2024
Safety, Pharmacokinetics, Clinical Efficacy and Exploratory Biomarker Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Enpatoran in Active Systemic and Cutaneous Lupus Erythematosus (SLE/CLE)
Torsten Witte¹, Ruth Fernandez Ruiz², Nadezda Abramova³, Dominika Weinelt³, Flavie Moreau⁴, Lena Klopp-Schulze⁵, Jamie Shaw⁶, Deborah Denis⁷ and Joerg Wenzel⁸, ¹Dept of Immunology and Rheumatology, Hannover, Germany, ²Global Clinical Development, EMD Serono, Billerica, MA, ³Global Patient Safety, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁴Global Biostatistics, EMD Serono, Billerica, MA, ⁵Quantitative Pharmacology, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁶Companion Diagnostics and Biomarker Strategy, EMD Serono, Billerica, MA, ⁷EMD Serono, Rockland, MA, ⁸Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany
Background/Purpose: Enpatoran, a highly selective, potent and reversible dual toll-like receptor 7/8 (TLR7/8) inhibitor, targets key innate and adaptive immune processes involved in the pathogenesis…

« Previous Page
1
…
6
7
8
9
10
…
54
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].